Unknown

Dataset Information

0

H2Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts.


ABSTRACT: Human epidermal growth factor receptor 2 (HER2) is reported to be overexpressed in breast cancers and is associated with poor clinical outcome. Trastuzumab is a humanized anti-HER2 antibody that offers significant survival benefits to patients with HER2-overexpressing breast cancer. In this study, a novel anti-HER2 monoclonal antibody (mAb), H2Mab-19 (IgG2b, kappa) was developed. Antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antitumor activity of H2Mab-19 were investigated using both breast cancer and oral cancer cell lines. H2Mab-19 demonstrated cytotoxicity in BT-474 (a human breast cancer cell line) and HSC-2 or SAS (human oral cancer cell lines). H2Mab-19 also possessed both ADCC and CDC activity against BT-474, HSC-2, and SAS cell lines. In comparison to control mouse IgG, H2Mab-19 significantly reduced tumor development in BT-474, HSC-2, and SAS xenografts. Collectively, these results suggest that treatment with H2Mab-19 may be a useful therapy for patients with HER2-expressing breast and oral cancers.

SUBMITTER: Takei J 

PROVIDER: S-EPMC7388441 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

H<sub>2</sub>Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts.

Takei Junko J   Kaneko Mika Kato MK   Ohishi Tomokazu T   Kawada Manabu M   Harada Hiroyuki H   Kato Yukinari Y  

Experimental and therapeutic medicine 20200518 2


Human epidermal growth factor receptor 2 (HER2) is reported to be overexpressed in breast cancers and is associated with poor clinical outcome. Trastuzumab is a humanized anti-HER2 antibody that offers significant survival benefits to patients with HER2-overexpressing breast cancer. In this study, a novel anti-HER2 monoclonal antibody (mAb), H<sub>2</sub>Mab-19 (IgG<sub>2b</sub>, kappa) was developed. Antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and a  ...[more]

Similar Datasets

| S-EPMC7640354 | biostudies-literature
| S-EPMC8261196 | biostudies-literature
| S-EPMC7550977 | biostudies-literature
| S-EPMC7475192 | biostudies-literature
| S-EPMC5976479 | biostudies-literature
| S-EPMC4446100 | biostudies-literature
| S-EPMC7559861 | biostudies-literature
| S-EPMC7608076 | biostudies-literature
| S-EPMC7068343 | biostudies-literature
| S-EPMC9774109 | biostudies-literature